BioCardia (BCDA) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

BCDA BioCardia

Watchlist

3.320
+0.420+14.48%

Close Aug 16 16:00 ET

2.800
-0.520-15.66%

Post 20:01 ET

7.05MMarket Cap-622P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | HC Wainwright & Co. Maintains Buy on BioCardia, Adjusts Price Target To $25 (1-15 Reverse Stock Split)
BenzingaAug 16 13:53 ET
Earnings Call: BioCardia Reports Progress in Heart Failure Trials
InvestingAug 14 20:10 ET
Earnings Call Summary | BioCardia(BCDA.US) Q2 2024 Earnings Conference
moomoo AIAug 14 07:59 ET · Conference Call
Express News | BioCardia Inc : H.c. Wainwright Adjusts Target Price to $25 From $4 to Reflect 1-for-15 Reverse Stock Split
ReutersAug 14 06:36 ET
BioCardia, Inc. (BCDA) Q2 2024 Earnings Call Transcript
Earnings Call TranscriptsAug 13 19:53 ET
Express News | BioCardia Inc- Qtrly Shr Loss $0.88
ReutersAug 13 16:33 ET

Comments

Jaguar8

Jul 17 06:01

NEWS

$BioCardia (BCDA.US)$
BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application
BioCardia, Inc. [Nasdaq: BCDA] has been granted U.S. Patent No. 12,036,371 for its Morph DNA multi-directional steerable catheter transseptal application. The patent, expiring in 2035, covers medical methods for transseptal access to the heart using steerable introducers based on BioCardia's Morph DNA technology. This innovation enhances shareholder...

TrendTrader

Jul 15 15:04

Over 4.7 has room to 5.3 and 5.7

$BioCardia (BCDA.US)$

Trytosaveabit

Jul 15 15:03

And you?

$BioCardia (BCDA.US)$ Hehehe

Jaguar8

Jul 8 06:00

NEWS

$BioCardia (BCDA.US)$
CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction
CellProthera and BioCardia announced the successful completion of a collaborative Phase II trial of ProtheraCytes for treating acute myocardial infarction (AMI). The EXCELLENT Trial results showed that the transendocardial injection of ProtheraCytes, which are autologous, expanded CD34+ stem cells, in combination with standard care, helpe...

Trytosaveabit

Jun 12 06:41

Insider buy

$BioCardia (BCDA.US)$ Officer Altman Peter purchased 1,000 shares of common stock on Jun 10, 2024 at an average price of $3.36 for a total value of $3,360.

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

Concept

Top Gainers Yesterday

Intraday-1.56%

BCDA BioCardia

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target